Pune, March 27, 2020 (GLOBE NEWSWIRE) -- The global Hunter syndrome treatment market size is predicted to reach USD 1,118.4 million by 2026, exhibiting a CAGR of 6.0% during the forecast period. The increasing R&D investments by key players for the development of novel therapies to treat rare diseases in patients will be critical factor in boosting the Hunter syndrome treatment market growth during the forecast period. Moreover, the rising clinical studies for diabetes and coronary artery disease (CAD) will have a positive impact on market during the forecast period. In addition, the surge in rare and genetic diseases will uplift the Hunter syndrome treatment market share. According to the Genetic and Rare Diseases Information Center (GARD), there can be an estimated 7,000 rare diseases and the total number of individuals in the U.S. from these rare diseases can be 25-30 million.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/hunter-syndrome-treatment-market-102536
According to the report, published by Fortune Business Insights, tiled “Hunter Syndrome Treatment Market Size, Share & Industry Analysis, By Treatment (Enzyme Replacement Therapy (ERT), and Others), By Route of Administration (Intravenous, and Intracerebroventricular (ICV)/ Intrathecal), By End User (Hospitals, Specialty Clinics and Others), and Regional Forecast, 2019-2026” the market size stood at USD 702.4 million in 2018. The Hunter syndrome treatment market report focuses on demonstrating a complete assessment of the market. It contains facts, thoughtful insights, historical information, industry-validated market information, and projections with a suitable set of assumptions and methodology. It offers valuable insights into all the notable developments of the market. It is created after extensive research followed by an all-encompassing analysis to benefit companies, stakeholders, financers, and potential investors. Moreover, it also includes product launches, acquisitions, collaborations and partnerships, and industry developments.
Competitive Landscape:
Agreement between Clinigen K.K. and GC Pharma to Enable Growth
Clinigen K.K, a Japanese licensed medical supplier, and GC Pharma, a biopharmaceutical company announced a licensing agreement for the manufacturing and commercialization of Hunterase (Idursulfase-beta) ICV, a human recombinant iduronate-2-sulfatase (IDS) used in enzyme replacement therapy for the treatment of Hunter syndrome. The agreement between the two companies can be a critical factor in fostering the growth of the market owing to the methods to aid severe patients and therefore improve their condition.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/hunter-syndrome-treatment-market-102536
Furthermore, Hunterase ICV will be directly delivered to cerebral ventricles by intracerebroventricular (ICV) administration, in order to reach the cells of the brain and central nervous system. Furthermore, Yoshikazu Nakamura, Representative Director at Clinigen K.K, said “Hunter Syndrome is a complex disease with unmet medical need. We earnestly hope that this product provides significant benefit to patients in Japan.” In addition, President at GC Pharma, Eun Chul, said in statement, “we are delighted to further enhance the value of Hunterase through this partnership, our efforts to make substantial differences in the lives of those with Hunter syndrome in all markets will continue by providing new treatment environments and opportunities.”
Competitive Landscape:
The market in North America generated a revenue of USD 358.9 million in 2018 and is predicted to grow rapidly during the forecast period. The growth in the region is attributed to the high diagnosis and treatment for rare diseases. The growing reimbursement policies for therapies will have a positive impact on the market in the region. Asia Pacific is predicted to witness high growth rate in the forthcoming years owing to the developing healthcare infrastructure. Also, the presence of major players in the region will bolster healthy growth in Asia Pacific. In addition, ongoing clinical trials will boost the Hunter syndrome treatment market trends in the forthcoming years. For instance, the Phase 1/2 clinical trial conducted and initiated by Prof. Torayuki Okuyama in National Center for Child Health and Development in Japan showed a significant decrease in Heparan sulfate which causes mental retardation.
List of the Key Companies in the Hunter Syndrome Treatment Market are:
- Shire (Takeda Pharmaceutical Company Limited)
- Denali Therapeutics
- ArmaGen
- Inventiva
- Green Cross Corp. (GC Pharma)
- CANbridge Life Sciences Ltd.
- JCR Pharmaceuticals Co., Ltd.
- REGENXBIO Inc.
- Sangamo Therapeutics
- Others
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/hunter-syndrome-treatment-market-102536
Detailed Table of Content:
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Pipeline Analysis
- Key Industry Developments
- Regulatory Scenario by Key Regions
- Overview of Emerging Treatments for Hunter Syndrome
- Reimbursement Scenario by Key Regions
- Global Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2014-2025
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Treatment
- Enzyme Replacement Therapy (ERT)
- Others
- Market Analysis, Insights and Forecast – By Route of Administration
- Intravenous
- Intracerebroventricular (ICV)/ Intrathecal
- Market Analysis, Insights and Forecast – By End User
- Hospitals
- Specialty Clinics
- Others
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Rest of the World
Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/hunter-syndrome-treatment-market-102536
Have a Look at Related Reports:
Orphan Drugs Market Size, Share and Global Trend By Therapy Area (Oncology, Blood, CNS, Endocrine, Cardiovascular, Respiratory, Immunomodulatory), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales) and Geography Forecast till 2025
Fabrys Disease Treatment Market Size, Share and Global Trend By Treatment (Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Chaperone Treatment, Others), By Route of Administration (Oral, Intravenous, Others) and Geography Forecast till 2026
Morquio Syndrome Treatment Market Size, Share and Global Trend By Treatment (Enzyme Replacement Therapy), By Disease Type (Morquio A, Morquio B), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Geography Forecast till 2026
Pompe Disease Treatment Market Size, Share and Global Trend By Treatment (Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Chaperone-Advanced Replacement Therapy (CART), Others), By Rout of Administration (Oral, Intravenous, Others), By Distribution channel (Hospital & Clinics Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Geography Forecast till 2026
Immunoglobulin Market Size, Share and Industry Analysis By Route of Administration (Intravenous (IV), Subcutaneous (SC)), By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), By Form (Liqui, Lyophilized), By End User (Hospitals, Clinics, Homecare), and Regional Forecast 2018-2025
Plasma Fractionation Market Size, Share & Industry Analysis, By Product Type (Albumin, Immunoglobulin (Intravenous Immunoglobulin and Subcutaneous Immunoglobulin), Coagulation Factors, Protease Inhibitors and Others), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology and Others), By End User (Hospitals & Clinics,), and Geography Forecast 2019-2026
Diabetes Drugs Market Size, Share and Industry Analysis By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors), Diabetes Type (Type 1, Type 2), Route of Administration (Oral, Subcutaneous, Intravenous), Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail Pharmacies) & Regional Forecast 2019 – 2026
Idiopathic Inflammatory Myopathy Treatment Market Size, Share & Industry Analysis, By Disease Type (Dermatomyositis, Polymyositis, Necrotizing Autoimmune Myopathy, Others), By Treatment (Corticosteroids, Immunosuppressants, Others), By Route of Administration (Oral, Intravenous, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026
Injectable Drug Delivery Market Size, Share and Industry Analysis By Device Type (Conventional Injectable, Pre-filled Syringes, Auto-injectors, Pen-injectors, Others), By Application (Autoimmune Disorders, Diabetes, Pain Management, Aesthetic Treatments, Others), By Route of Administration (Subcutaneous, Intravenous, Intramuscular, Others), By End-User (Hospitals, Home Care Settings, Clinics, Others), and Regional Forecast 2019-2026
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/hunter-syndrome-treatment-market-9690